IP Library Granted Patent US 7,183,410
Granted Patent B2
US 7,183,410 · App. 10/210,474 · Granted Feb 27, 2007

Stable polymorph of flibanserin

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,183,410
App. No.
10/210,474
Granted
Feb 27, 2007
Kind
B2
Abstract

The invention relates to the polymorph A of flibanserin, to a technical process for the preparation thereof, as well as to the use thereof for preparing medicaments.

Claims (14)

1. A process for preparing form A of flibanserin 1 having an endothermic maximum at about 161° C. which occurs during thermal analysis using DSC,

said process comprising:

(a) reacting a benzimidazolone 2

 wherein R denotes a suitable amino protecting group, with a piperazine 3

 wherein X is a leaving group selected from chlorine, bromine, iodine, methanesulphonate, trifluoromethanesulphonate and para-toluenesulphonate, in a suitable solvent selected from water, alcohols, mixtures of water with alcohols, polar aprotic solvents and mixtures of polar aprotic solvents with water, in the presence of a suitable base, and

(b) cleaving the amino protecting group R under suitable cleaving conditions.

2. A process according to claim 1 , wherein the reaction of 2 with 3 is conducted at a temperature of at least 50° C.

3. A process according to claim 2 , wherein heating is conducted for about 10 minutes to about 12 hours.

4. A process for preparing flibanserin 1 comprising form A having an endothermic maximum at about 161° C. which occurs during thermal analysis using DSC,

said process comprising:

(a) reacting a benzimidazolone 2

 wherein R denotes a suitable amino protecting group, with a piperazine 3

5. A process according to claim 4 , wherein the reaction of 2 with 3 is conducted at a temperature of at least 50° C.

6. A process according to claim 5 , wherein heating is conducted for about 10 minutes to about 12 hours.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: BARCLAYS BANK PLC
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0194 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: THE BANK OF NEW YORK MELLON
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0236 →
SECURITY INTEREST Recorded Feb 25, 2021
From: SPROUT PHARMACEUTICALS, INC.
To: GOODRICH, BRAXTON; WHITEHEAD, ROBERT
Reel/Frame 055407/0810 →
SECURITY INTEREST Recorded Jul 19, 2017
From: SPROUT PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0950 →
SECURITY AGREEMENT Recorded Dec 21, 2015
From: SPROUT PHARMACEUTICALS, INC., AS GRANTOR; UNILENS VISION INC., AS GRANTOR; COMMONWEALTH LABORATORIES, LLC, AS GRANTOR; SYNERGETICS USA, INC., AS GRANTOR
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 037357/0490 →